Crown Electrokinetics Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders??? Equity

Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Series A Preferred Stock Preferred Stock	Series B Preferred Stock Preferred Stock	Series C Preferred Stock Preferred Stock	Series D Preferred Stock Preferred Stock	Series E Preferred Stock Preferred Stock	Series F Preferred Stock Preferred Stock	Series F-1 Preferred Stock Preferred Stock	Series F-2 Preferred Stock Preferred Stock	Common Stock Common Stock
Beginning balance (in shares) at Dec. 31, 2022					251	1,443	500,756	1,058	0				338,033
Beginning balance at Dec. 31, 2022	$ 530		$ 88,533	$ (88,005)	$ 0	$ 0	$ 0	$ 0	$ 0				$ 2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock warrants (in shares)													109,257
Exercise of common stock warrants	2,062		2,061										$ 1
Issuance of common stock in connection with conversion of notes (in shares)													31,466
Issuance of common stock in connection with conversion of notes	516		516
Commitment to issue shares of common stock in connection with March waiver agreement	298		298
Deemed dividend for repricing of Series D preferred stock			6	(6)
Issuance of common stock/at-the-market offering, net of offering costs (in Shares)													211,667
Issuance of common stock/at-the-market offering, net of offering costs	2,107		2,106										$ 1
Issuance of Series E preferred stock in connection with LOC (in shares)									5,000
Issuance of Series E preferred stock in connection with LOC	4,350		4,350
Stock-based compensation (in shares)													38,335
Stock-based compensation	181		181
Net loss	(2,300)			(2,300)
Ending balance (in shares) at Mar. 31, 2023					251	1,443	500,756	1,058	5,000				728,758
Ending balance at Mar. 31, 2023	7,744		98,051	(90,311)	$ 0	$ 0	$ 0	$ 0	$ 0				$ 4
Beginning balance (in shares) at Dec. 31, 2023					251	1,443	500,756	0	0	4,448	653	1,153	25,744,158
Beginning balance at Dec. 31, 2023	4,677		121,665	(116,995)	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity line of credit (in shares)													21,133,689
Issuance of common stock in connection with equity line of credit	1,391	$ 3	1,388
Issuance of common stock/at-the-market offering, net of offering costs (in Shares)													4,824,382
Issuance of common stock/at-the-market offering, net of offering costs	588		588
Stock-based compensation	274		274
Net loss	(4,612)			(4,612)
Ending balance (in shares) at Mar. 31, 2024					251	1,443	500,756	0	0	4,448	653	1,153	51,702,229
Ending balance at Mar. 31, 2024	$ 2,318		$ 123,915	$ (121,607)	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 10